Benitec Biopharma Inc. (BNTC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -51.19M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 23.39M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-51.19M | (m) | (m) | $23.39M | (m) | (m) |
| 2026-03-31 | $-46.60M | (m) | (m) | $18.37M | (m) | (m) |
| 2025-12-31 | $-48.35M | (m) | (m) | $18.57M | (m) | (m) |
| 2025-09-30 | $-45.78M | (m) | (m) | $18.12M | (m) | (m) |
| 2025-06-30 | $-41.77M | (m) | (m) | $18.33M | (m) | (m) |
| 2025-03-31 | $-30.14M | (m) | (m) | $18.15M | (m) | (m) |
| 2024-12-31 | $-24.09M | (m) | (m) | $14.73M | (m) | (m) |
| 2024-09-30 | $-22.41M | (m) | (m) | $14.77M | (m) | (m) |
| 2024-06-30 | $-22.49M | (m) | (m) | $15.61M | (m) | (m) |
| 2024-03-31 | $-21.49M | (m) | (m) | $15.28M | (m) | (m) |
| 2023-12-31 | $-21.69M | (m) | (m) | $15.88M | (m) | (m) |
| 2023-09-30 | $-20.38M | (m) | (m) | $14.54M | (m) | (m) |
| 2023-06-30 | $-19.08M | (m) | (m) | $12.77M | (m) | (m) |
| 2023-03-31 | $-19.27M | (m) | (m) | $12.76M | (m) | (m) |
| 2022-12-31 | $-18.39M | (m) | (m) | $11.77M | (m) | (m) |
| 2022-09-30 | $-17.61M | (m) | (m) | $11.15M | (m) | (m) |
| 2022-06-30 | $-17.85M | (m) | (m) | $11.27M | (m) | (m) |
| 2022-03-31 | $-16.97M | $75.00K | (m) | $10.42M | (m) | -22628.00% |
| 2021-12-31 | $-17.30M | $28.00K | (m) | $11.00M | (m) | -61803.57% |
| 2021-09-30 | $-15.73M | $4.00K | (m) | $9.03M | (m) | -393200.00% |
| 2021-06-30 | $-13.60M | $59.00K | (m) | $7.02M | (m) | -23044.07% |
| 2021-03-31 | $-12.63M | $22.00K | (m) | $5.61M | (m) | -57400.00% |
| 2020-12-31 | $-10.95M | $48.00K | (m) | $3.92M | (m) | -22816.67% |
| 2020-09-30 | $-9.80M | $124.00K | (m) | $3.35M | (m) | -7907.26% |
| 2020-06-30 | $-8.28M | $102.00K | (m) | $3.00M | (m) | -8118.63% |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $2.58M | $12.20M | (m) | $4.57M | (m) | 21.17% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |